Medicare is starting to examine RUC recommendations more closely
Although industry groups like America’s Health Insurance Plans have long argued that the absolute driver of premium rates is provider fees, the fact has received renewed attention in recent months. Perhaps it’s the growing body of evidence that can’t be ignored or the novelty of blaming insurers wearing off, but the issue finally seems to have come to the forefront.
Suzanne Delbanco, executive director of Catalyst for Payment Reform (CPR), says observers are catching on to the effects of provider consolidation in terms of price leverage. It’s all too easy to point to the aging population, insurance administration or costly technologies as reasons for high costs.
“In fact, right now it’s pricing,” says Delbanco. “That on the one hand is depressing, and on the other hand gives me cause for optimism because that’s something that can be negotiated.”
She also notes that the Relative Value Scale Update Committee (RUC), a 29-member physician panel that advises government health officials on reimbursement, bears a closer look. Medicare historically has accepted the RUC’s recommended pay scale for physician services without question.
However, Delbanco says, Medicare is scrutinizing the RUC recommendations more than it used to and pushing back.
“People are finally realizing that it’s not something that we can just ignore, and let it continue to operate behind closed doors,” she says.
Of particular concern is the dominant presence of specialists on the RUC and the way its secret-ballot rate determinations seem to skew in specialists’ favor. Delbanco believes increased price transparency and a critical review of the RUC will go a long way toward dampening price variation in healthcare.
She also participates in the National Commission on Physician Payment Reform, which last month released a set of recommendations including an overhaul of the RUC. Specifically, the commission calls for more diversity on the physician panel and transparent, evidence-based processes to validate RUC decisions.
Medicare Patients with PAH Face High Out-of-Pocket Costs | 2024 ATS
May 19th 2024Medicare patients who have pulmonary arterial hypertension and who are eligible for the low-income subsidy often have advanced disease, require prolonged disability insurance and face financial hardships, according to a poster at the annual ATS meeting.
Read More
FDA Updates for Week of May 13: First Bispecific Antibody for Solid Tumor
May 18th 2024The FDA has approved a new type of bispecific antibody to treat small cell lung cancer and an additional indication for Breyanzi for patients with follicular lymphoma. The agency has set review date for gene therapy for enzyme deficiency. In addition, Biogen have Eisai hve begun a rolling submission of subcutaneous Leqembi for Alzheimer’s disease.
Read More
Dr. Glaucomflecken the Opening Speaker Today at the 2024 ATS Meeting | 2024 ATS
May 18th 2024William Flanary, M.D.., has a huge social media following as Dr. Glaucomflecken, a character he created on Twitter when he was an ophthalmology resident in Iowa. More than 13,400 people have registered to attend the American Thoracic Society (ATS) International Conference, which is being held this weekend at the San Diego Convention Center.
Read More